Encycle Therapeutics
Toronto, Ontario, Canada
About Encycle Therapeutics
Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation, and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.1M
- Funding stage: M&A
- Last round: Series Unknown (Sep 2015)
- Website: encycletherapeutics.com
- Phone: +1 (647) 258-4500
Industries & Categories
Biotechnology, Chemical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/encycle-therapeutics-2546974 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.